Nb100 2437

The following primary antibodies were used in the study including anti-CXCR4 (ab124824, AbCam), anti-TRAIL (AF1121, R&D), anti-c-Kit (AF1356, Novus Biological), anti-CD47 (ab175388, Abcam), anti-Fasl (ab15285, Abcam), anti-PDL1 (NBP1-76769, Novus Biological), anti-CD4 (ab183685, Abcam), anti-SSEA1 (ab16285, Abcam), anti-Oct4 (ab184665, Abcam), anti-Sox2 (MAB2018R-100, R&D), anti-Nanos3 (ab70001, Abcam), anti-Ifitm3 (ab109429, Abcam), anti-Stellar (Invitrogen, PA5-34601), anti-PRDM14 (ab187881, Abcam), anti-Vasa (ab27591, Abcam), anti-DAZL (NB100-2437, Novus biologicals), anti-SMAD2 (ab33875, Abcam).

Cells were cultured on coverslips. fixed with 4% paraformaldehyde and then blocked in PBS with 5% BSA and 0.05% Triton-X-100. Cells or tissue sections were incubated overnight at 4 °C with various primary antibodies, including anti-POU5F1 (ab184665, Abcam), anti-Sox2 (MAB2018R-100, R&D), anti-Nanog (NB100-58842, Novus Biologicals), anti-Nanos3 (ab70001, Abcam), anti-DDX4 (ab27591, Abcam), SCP3 (ab 15,093, Abcam) or anti-DAZL (NB100-2437, Novus biologicals). Next, the cells were stained with Cy3 fluorescent dye-conjugated secondary antibodies (Jackson) and 4,6-diamidino-2-phenylindole (DAPI; Invitrogen), while the tissue sections were stained with haematoxylin. The cells just were stained with Cy3 fluorescent dye-conjugated secondary antibodies (Jackson) and 4,6-diamidino-2-phenylindole (DAPI; Invitrogen) as control.